From this morning's Earlybird:

• "The generic drug industry, outmanned and outspent on the lobbying front compared to its name-brand counterparts, has been struggling to be heard on Capitol Hill throughout the health care debate," Roll Call (subscription) reports. "The generic industry will be zeroing in on provisions adapted by key committees in both chambers that would shut it out of the biologic drug market for at least 12 years."

• "Former Bush administration official and lobbyist Tommy Thompson is the latest Republican to lash out at the Democratic National Committee for apparently misusing his stance on health care reform. The DNC over the weekend reportedly pulled a television advertisement featuring Thompson, former Sen. Bob Dole (Kan.) and other Republicans who apparently supported a White House-led charge to fix the nation's insurance woes," Roll Call (subscription) reports.

• "Even after Tuesday's Senate Finance Committee vote brought sighs of relief and dismay up and down K Street, lobbyists for many narrowly focused interest groups are still holding their breaths, waiting to see if their proposals will become part of any final healthcare bill," CongressDaily AM (subscription) reports.